S&P 500   4,957.80 (-0.36%)
DOW   38,439.70 (-0.32%)
QQQ   423.53 (-0.89%)
AAPL   181.40 (-0.09%)
MSFT   399.50 (-0.82%)
META   466.71 (-0.96%)
GOOGL   142.12 (+0.71%)
AMZN   167.80 (+0.43%)
TSLA   192.91 (-0.44%)
NVDA   671.14 (-3.37%)
NIO   6.03 (+1.17%)
AMD   163.12 (-1.55%)
BABA   75.85 (+3.71%)
T   16.97 (+0.35%)
F   12.10 (-1.22%)
MU   80.47 (-0.30%)
CGC   3.32 (-6.21%)
GE   148.56 (-0.04%)
DIS   107.72 (-1.57%)
AMC   4.57 (-1.93%)
PFE   27.51 (-0.29%)
PYPL   57.82 (-1.38%)
XOM   104.55 (+1.75%)
S&P 500   4,957.80 (-0.36%)
DOW   38,439.70 (-0.32%)
QQQ   423.53 (-0.89%)
AAPL   181.40 (-0.09%)
MSFT   399.50 (-0.82%)
META   466.71 (-0.96%)
GOOGL   142.12 (+0.71%)
AMZN   167.80 (+0.43%)
TSLA   192.91 (-0.44%)
NVDA   671.14 (-3.37%)
NIO   6.03 (+1.17%)
AMD   163.12 (-1.55%)
BABA   75.85 (+3.71%)
T   16.97 (+0.35%)
F   12.10 (-1.22%)
MU   80.47 (-0.30%)
CGC   3.32 (-6.21%)
GE   148.56 (-0.04%)
DIS   107.72 (-1.57%)
AMC   4.57 (-1.93%)
PFE   27.51 (-0.29%)
PYPL   57.82 (-1.38%)
XOM   104.55 (+1.75%)
S&P 500   4,957.80 (-0.36%)
DOW   38,439.70 (-0.32%)
QQQ   423.53 (-0.89%)
AAPL   181.40 (-0.09%)
MSFT   399.50 (-0.82%)
META   466.71 (-0.96%)
GOOGL   142.12 (+0.71%)
AMZN   167.80 (+0.43%)
TSLA   192.91 (-0.44%)
NVDA   671.14 (-3.37%)
NIO   6.03 (+1.17%)
AMD   163.12 (-1.55%)
BABA   75.85 (+3.71%)
T   16.97 (+0.35%)
F   12.10 (-1.22%)
MU   80.47 (-0.30%)
CGC   3.32 (-6.21%)
GE   148.56 (-0.04%)
DIS   107.72 (-1.57%)
AMC   4.57 (-1.93%)
PFE   27.51 (-0.29%)
PYPL   57.82 (-1.38%)
XOM   104.55 (+1.75%)
S&P 500   4,957.80 (-0.36%)
DOW   38,439.70 (-0.32%)
QQQ   423.53 (-0.89%)
AAPL   181.40 (-0.09%)
MSFT   399.50 (-0.82%)
META   466.71 (-0.96%)
GOOGL   142.12 (+0.71%)
AMZN   167.80 (+0.43%)
TSLA   192.91 (-0.44%)
NVDA   671.14 (-3.37%)
NIO   6.03 (+1.17%)
AMD   163.12 (-1.55%)
BABA   75.85 (+3.71%)
T   16.97 (+0.35%)
F   12.10 (-1.22%)
MU   80.47 (-0.30%)
CGC   3.32 (-6.21%)
GE   148.56 (-0.04%)
DIS   107.72 (-1.57%)
AMC   4.57 (-1.93%)
PFE   27.51 (-0.29%)
PYPL   57.82 (-1.38%)
XOM   104.55 (+1.75%)
NYSE:CLVT

Clarivate (CLVT) Stock Price, News & Analysis

$8.80
-0.13 (-1.46%)
(As of 12:33 PM ET)
Today's Range
$8.73
$8.87
50-Day Range
$8.45
$9.44
52-Week Range
$6.07
$11.99
Volume
736,180 shs
Average Volume
3.36 million shs
Market Capitalization
$5.84 billion
P/E Ratio
33.85
Dividend Yield
N/A
Price Target
$8.33

Clarivate MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
5.3% Downside
$8.33 Price Target
Short Interest
Bearish
9.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.23mentions of Clarivate in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.06%
From $0.62 to $0.67 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Computer And Technology Sector

949th out of 1,162 stocks

Data Processing & Preparation Industry

81st out of 116 stocks


CLVT stock logo

About Clarivate Stock (NYSE:CLVT)

Clarivate Plc, an information, analytics, and workflow company, provides structured information and analytics for discovery, development, protection, commercialization, and measurement of scientific research, innovations, and brands. The company operates through three segments: Academia and Government, Life Sciences and Healthcare, and Intellectual Property. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ProQuest One, Pivot, Polaris, eBook Central, Vegs, Alma, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis products for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs; and Real World Data, Dialog, Drug Safety Triager, and healthcare and data solutions. The company also provides Derwent products, which include Derwent Innovation, Innography, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; and CompuMark products, such as trademark screening, searching, and watching products and services. It serves government and academic institutions, and life science and healthcare companies in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc was founded in 1864 and is headquartered in London, the United Kingdom.

CLVT Stock Price History

CLVT Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Clarivate (CLVT) Scheduled to Post Quarterly Earnings on Tuesday
CLVT Mar 2024 10.000 put
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Why Clarivate Plc (NYSE:CLVT) Could Be Worth Watching
Wells Fargo Downgrades Clarivate (CLVT)
See More Headlines
Receive CLVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clarivate and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
2/21/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Data processing & preparation
Sub-Industry
N/A
Fax
N/A
Employees
11,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.33
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
-6.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
9 Analysts

Profitability

Net Income
$-3,960,200,000.00
Pretax Margin
3.63%

Debt

Sales & Book Value

Annual Sales
$2.66 billion
Cash Flow
$1.86 per share
Book Value
$8.04 per share

Miscellaneous

Free Float
512,748,000
Market Cap
$5.94 billion
Optionable
Optionable
Beta
1.32
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Jonathan Gear (Age 53)
    CEO & Director
    Comp: $1.3M
  • Mr. Jonathan M. Collins (Age 44)
    Executive VP & CFO
    Comp: $1.96M
  • Mr. Gordon Samson (Age 58)
    President of Intellectual Property
    Comp: $1.02M
  • Mr. Michael Easton (Age 51)
    Senior VP of Finance & Chief Accounting Officer
  • Mr. William E. Graff
    Chief Information Officer
  • Mr. Mark J. Donohue
    Head of Investor Relations
  • Ms. Melanie D. Margolin J.D. (Age 52)
    Chief Legal Officer
  • Ms. Tabita Andersson
    Senior Vice President of Communications & Brand
  • Ms. Julia M. Wilson (Age 61)
    Chief People Officer
  • Mr. Richard C. Finch
    Global Head of Life Sciences Consulting Services














CLVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Clarivate stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clarivate in the last twelve months. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CLVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVT, but not buy additional shares or sell existing shares.
View CLVT analyst ratings
or view top-rated stocks.

What is Clarivate's stock price target for 2024?

9 brokerages have issued 12-month price objectives for Clarivate's stock. Their CLVT share price targets range from $6.00 to $11.00. On average, they anticipate the company's stock price to reach $8.33 in the next twelve months. This suggests that the stock has a possible downside of 5.3%.
View analysts price targets for CLVT
or view top-rated stocks among Wall Street analysts.

How have CLVT shares performed in 2024?

Clarivate's stock was trading at $9.26 on January 1st, 2024. Since then, CLVT stock has decreased by 5.0% and is now trading at $8.80.
View the best growth stocks for 2024 here
.

Are investors shorting Clarivate?

Clarivate saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 32,760,000 shares, an increase of 6.0% from the December 31st total of 30,910,000 shares. Based on an average daily volume of 5,630,000 shares, the days-to-cover ratio is currently 5.8 days. Currently, 8.8% of the company's shares are sold short.
View Clarivate's Short Interest
.

When is Clarivate's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CLVT earnings forecast
.

How can I listen to Clarivate's earnings call?

Clarivate will be holding an earnings conference call on Tuesday, February 27th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Clarivate's earnings last quarter?

Clarivate Plc (NYSE:CLVT) announced its quarterly earnings data on Tuesday, November, 7th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.18 by $0.03. The business earned $647.20 million during the quarter, compared to the consensus estimate of $631.41 million. Clarivate had a trailing twelve-month return on equity of 9.47% and a net margin of 9.77%. Clarivate's revenue was up 1.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.18 earnings per share.

What ETF holds Clarivate's stock ?

iShares MSCI USA Size Factor ETF holds 68,505 shares of CLVT stock, representing 0.20% of its portfolio.

Who are Clarivate's major shareholders?

Clarivate's stock is owned by a variety of institutional and retail investors. Top institutional investors include Exor N.V. (9.90%), Generation Investment Management LLP (4.42%), Baupost Group LLC MA (3.84%), Glenview Capital Management LLC (3.71%), Vanguard Group Inc. (1.24%) and Dimensional Fund Advisors LP (1.18%). Insiders that own company stock include Andrew Miles Snyder, Blucher Sheryl G Von, Corp Onex, James Gordon Samson, Jeff Roy, Mukhtar Ahmed, Richard Hanks and Richard Roedel.
View institutional ownership trends
.

How do I buy shares of Clarivate?

Shares of CLVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CLVT) was last updated on 2/21/2024 by MarketBeat.com Staff